Its actions include stimulating insulin production, slowing down digestion, and, significantly for weight loss, curbing appetite by making you feel full and causing the stomach to empty more slowly
Second Natures peer-reviewed study published in JMIR Formative Research (2025) compared both medications within our programme: 3 Tirzepatide (Mounjaro) cohort (209 people): 22.1% average weight loss at 12 months 95.2% achieved at least 10% weight loss 83.7% achieved at least 15% weight loss Semaglutide (Wegovy) cohort (130 people): 17.1% average weight loss at 12 months 83.1% achieved at least 10% weight loss 56.2% achieved at least 15% weight loss Both cohorts exceeded clinical trial results, suggesting that comprehensive behavioural support enhances outcomes regardless of which medication you use
The actual science, in contrast, is still playing catch-up
Third-party testing verification This is non-negotiable
Presented in a pre-filled disposable pen, this product is engineered for controlled environments where accurate dosing and consistent results are essential
Amsterdam, The Netherlands: 2005